Salix Pharmaceuticals could be acquired for $190 per share

Salix Pharmaceuticals, a developer of medical devices and drugs for the prevention and treatment of gastrointestinal disorders, may be acquired for $190 per share, according to a Triangle Business Journal report.

Advertisement

Sterne Agee analysts predict there is a 55 percent probability that the company will be acquired at that price.

Salix Pharmaceuticals has been in contact with Allergan and Actavis for the discussion of a potential acquisition.

More articles on gastroenterology:
Dr. David Gottesman joins Cleveland Clinic
Are current endoscopy cleaning protocols enough?
Hudson Valley Hospital Center adds 2 gastroenterologists

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.